Loading...

Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 74.67 USD +0.3% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one BMY stock under the Base Case scenario is 88.84 USD. Compared to the current market price of 74.67 USD, Bristol-Myers Squibb Co is Undervalued by 16%.

The Intrinsic Value is calculated as the average of the two valuation methods:

BMY Intrinsic Value
Base Case
88.84 USD
Undervaluation 16%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Low 3-Year Average ROE
Positive Net Income
Positive 3-Year Average ROIC
Negative 1-Year Revenue Growth
60/100
Profitability
Score

Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Average Interest Coverage
Average D/E
Average Altman Z-Score
45/100
Solvency
Score

Bristol-Myers Squibb Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
78%
Gross Margin
25%
Operating Margin
14%
Net Margin
28%
FCF Margin
18%
ROE
11%
ROIC
Other

BMY Capital Structure
Bristol-Myers Squibb Co

Market Capitalization 159B USD
Total Debt 37.2B USD
Minority Interest 63M USD
Preferred Equity 0 USD
Cash and Equivalents 7.7B USD
Short-Term Investments 1.3B USD
Enterprise Value 187B USD

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 83.2 USD with a low forecast of 60.6 USD and a high forecast of 96.6 USD.

Lowest
Price Target
60.6 USD
19% Downside
Average
Price Target
83.2 USD
11% Upside
Highest
Price Target
96.6 USD
29% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

BMY Competitors
Bristol-Myers Squibb Co

BMY Suppliers & Customers
Bristol-Myers Squibb Co

Bristol-Myers Squibb Co has 93 key suppliers from 14 countries and 15 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
54
Johnson & Johnson
Pharmaceuticals
Omnicom Group Inc
Media
Ampco-Pittsburgh Corp
Metals & Mining
Abbvie Inc
Biotechnology
SailPoint Technologies Holdings Inc
Technology
Alexandria Real Estate Equities Inc
Real Estate
Bright Horizons Family Solutions Inc
Diversified Consumer Services
S
Signify Health Inc
Health Care
Cryoport Inc
Health Care
Fulcrum Therapeutics Inc
Pharmaceuticals
R
Royalty Pharma PLC
Pharmaceuticals
9
908 Devices Inc.
Electrical Equipment
Liquidity Services Inc
Retail
Schrodinger Inc
Health Care
I
Ikena Oncology Inc
Pharmaceuticals
Halozyme Therapeutics Inc
Biotechnology
E
Eiger BioPharmaceuticals Inc
Biotechnology
CytomX Therapeutics Inc
Biotechnology
Guardant Health Inc
Health Care
Idera Pharmaceuticals Inc
Biotechnology
Exelixis Inc
Biotechnology
Brooks Automation Inc
Semiconductors
Mirati Therapeutics Inc
Biotechnology
Aveo Pharmaceuticals Inc
Biotechnology
Rigel Pharmaceuticals Inc
Biotechnology
bluebird bio Inc
Biotechnology
FibroGen Inc
Biotechnology
AnaptysBio Inc
Biotechnology
Sutro Biopharma Inc
Biotechnology
Nektar Therapeutics
Pharmaceuticals
Avidity Biosciences Inc
Biotechnology
Lexicon Pharmaceuticals Inc
Biotechnology
Forma Therapeutics Holdings Inc
Biotechnology
Quanterix Corp
Life Sciences Tools & Services
Editas Medicine Inc
Biotechnology
TSR Inc
Technology
Concert Pharmaceuticals Inc
Biotechnology
Checkmate Pharmaceuticals Inc
Biotechnology
Agios Pharmaceuticals Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
Illumina Inc
Life Sciences Tools & Services
Replimune Group Inc
Biotechnology
PureTech Health PLC
Biotechnology
Molecular Templates Inc
Biotechnology
I
Intra-Cellular Therapies Inc
Pharmaceuticals
Clovis Oncology Inc
Biotechnology
Inhibrx Inc
Biotechnology
Ayala Pharmaceuticals Inc
Biotechnology
Atreca Inc
Biotechnology
Epizyme Inc
Biotechnology
O
Oncotelic Therapeutics Inc
Biotechnology
Globeimmune Inc
Biotechnology
Seagen Inc
Biotechnology
Gritstone bio Inc
Biotechnology
Suppliers Map

Bristol-Myers Squibb Co has 64 key customers from 8 countries and 5 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Ownership

BMY Insider Trading
Buy and sell transactions by insiders

Bristol-Myers Squibb Co insiders have only sold shares in the past 12 months.

During the last 12 months Bristol-Myers Squibb Co insiders have not bought any shares, and sold 156M USD worth of shares. The last transaction was made on Feb 6, 2023 by Powell Ann (EVP, Chief Human Resources), who sold 3.9M USD worth of BMY shares.

Sold
0-3
months
14.8M USD
2
3-6
months
66.6M USD
3
6-9
months
28.4M USD
2
9-12
months
45.8M USD
4
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
14.8M USD
N/A
-14.8M
6 Months
81.4M USD
N/A
-81.4M
9 Months
110M USD
N/A
-109.8M
12 Months
156M USD
N/A
-155.6M
Purchases
5
Sales
47
No transactions found
Why is insider trading important?

Shareholder Return

BMY Price
Bristol-Myers Squibb Co

1M 1M
+2%
6M 6M
+1%
1Y 1Y
+14%
3Y 3Y
+20%
5Y 5Y
+41%
Annual Price Range
74.67
52w Low
64.96
52w High
81.13
Price Metrics
Average Annual Return 4.21%
Standard Deviation of Annual Returns 15.87%
Max Drawdown -35%
Shares Statistics
Market Capitalization 159B USD
Shares Outstanding 2 135 260 032
Percentage of Shares Shorted 1.15%

Company Profile

Bristol-Myers Squibb Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

159B USD

Dividend Yield

3.02%

Description

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Contact

NEW YORK
New York City
430 E 29th St Fl 14
+12125464000.0
https://www.bms.com/

IPO

1929-07-05

Employees

32 200

Officers

Chairman & CEO
Dr. Giovanni Caforio M.D.
Exec. VP & CFO
Mr. David V. Elkins
Exec. VP & Gen. Counsel
Ms. Sandra Leung Esq.
Exec. VP & Chief Commercialization Officer
Dr. Christopher S. Boerner
Exec. VP and Pres of Research & Early Devel.
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.
Exec. VP and Chief Digital & Technology Officer
Mr. Greg Meyers
Show More
VP & Head of Investor Relations
Mr. Timothy Power
Sr. VP & Chief Compliance and Ethics Officer
Ms. Cari Gallman
Exec. VP & Chief HR Officer
Ms. Ann M. Powell Judge
Head of US Drug Makers - India
Mr. Jitendra Tyagi
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 88.84 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 74.67 USD, Bristol-Myers Squibb Co is Undervalued by 16%.